Development of a New Family of HIV Latency Regulators (LRAs) Targeting the Tat Viral Protein (TatLat)

Antiretroviral therapy (ART) prevents HIV from multiplying. However, if people living with HIV stop taking ART, the virus quickly reappears in their blood due to the random activation of hidden infected cells. These hidden cells contain HIV that is not active and do not produce the virus. These cells are a major challenge in finding a cure for HIV.

One of the most promising ways to get rid of these hidden infected cells is by activating them with special drugs called latency-reversing agents (LRAs). This process, known as the "shock-and-kill" strategy, involves waking up the hidden virus ("shock" phase) so that it can be destroyed by the body's immune system or by the virus itself ("kill" phase).

Investigators are developing new LRAs that target and activate a viral protein called Tat, which is necessary for the virus to start producing again and for reversing its dormant state.The lead compound, named D10, is the first of its kind to target the Tat protein. This compound has been patented and has shown activity in activating the virus in lab-grown cells. Now, investigators need to test its effectiveness on real target cells from people living with HIV.

Study Overview

• Status: Recruiting
• Conditions: HIV Infections
• Intervention / Treatment: Biological: Blood Sampling

Detailed Description

20 ml of blood (5 tubes of 4 ml each) will be collected from 24 people living with HIV who are on ART. The inclusion criteria for this study are: being HIV-positive, having an undetectable viral load for more than 12 months, and having a history of very low T-CD4 counts (nadir < 200 cells/mm³).

In the lab, investigators will isolate immune cells (PBMCs) from the blood using a special technique. These cells will then be placed in small wells and treated with LRAs for 18-20 hours. Investigators will measure the virus produced in the cell supernatant using two methods: q-RT-PCR for viral RNA and p24 ELISA for viral protein. The results will be analyzed using conventional statistical methods.

• Study Type: Observational
• Enrollment (Estimated): 24

Contacts and Locations

• Study Contact: Name: Alain MAKINSON, Pr; Phone Number: 04 67 33 83 40; Email: a-makinson@chu-montpellier.fr
• Study Contact Backup: Name: Bruno BEAUMELLE; Email: bruno.beaumelle@irim.cnrs.fr

Study Locations

• France
  • Montpellier, France, 34090
    • Recruiting
    • CHU de Montpellier
    • Contact: Phone Number: 0467335046; Email: a-makinson@chu-montpellier.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

The target population is aviremic HIV-positive individuals, with no age criterion, having a long history of HIV infection (nadir < 200 CD4/µL

Description

Inclusion Criteria:

• Patient aged 18 years or older
• HIV-positive
• On ART (antiretroviral therapy)
• HIV-1 RNA undetectable for more than 12 months
• Nadir CD4 count < 200/µL

Exclusion Criteria:

• Lack of antiretroviral treatment
• Immunosuppressive treatments
• History of cancer less than 5 years old
• Pregnant or breast-feeding women
• Persons protected by law (under guardianship or curators), persons under court protection
• Participating in another research project with an ongoing exclusion period
• Refusal to participate in research
• Subject not affiliated to a social security scheme, or not benefiting from such a scheme.

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Quantity of p24 in the cell supernatant 18-20 hours after the addition of the LRAs (Latency Reversing Agents)	Viral production is considered significant if the signal obtained from the p24 ELISA of these supernatants is more than twice the background observed in the absence of LRA	INCLUSION VISIT

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Quantity of viral RNA in the cell supernatant 18-20 hours after the addition of LRAs.	quantity of viral RNA in the cell supernatant 18-20 hours after the addition of LRAs.	INCLUSION VISIT
Measure the effective dose of D10 to reverse the latency of latent HIV-infected PBMCs	effective dose of D10 to reverse the latency of latent HIV-infected PBMCs	INCLUSION VISIT

Collaborators and Investigators

• Sponsor: University Hospital, Montpellier
• Collaborators: Université Montpellier; Centre National de la Recherche Scientifique, France

Study record dates

Study Major Dates

• Study Start (Actual): February 10, 2025
• Primary Completion (Estimated): February 10, 2027
• Study Completion (Estimated): February 10, 2027

Study Registration Dates

• First Submitted: May 28, 2024
• First Submitted That Met QC Criteria: May 28, 2024
• First Posted (Actual): June 4, 2024

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: February 20, 2025
• Last Verified: February 1, 2025

More Information

Terms related to this study

• Keywords: HIV-1; latency; Tat; transcription; latency reversing agents
• Additional Relevant MeSH Terms: Blood-Borne Infections; Urogenital Diseases; Genital Diseases; Immune System Diseases; Infections; RNA Virus Infections; Virus Diseases; Communicable Diseases; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Lentivirus Infections; Retroviridae Infections; Immunologic Deficiency Syndromes; HIV Infections
• Other Study ID Numbers: RECHMPL23_0276

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No